Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Burdock Root

Abstinence-Only Sex Education Debate Has High Financial Stakes, Washington Times Opinion Piece Says
By proposing to reduce funding for abstinence-only sex education programs, "the Obama administration has reignited America"s sex education debate," Washington Times columnist Cheryl Wetzstein writes in an opinion piece. She says that the "usual answers" she receives from abstinence-only opponents when she asks about their criticism of the programs is that abstinence-only education "doesn"t work, it leaves kids ignorant about how to use birth control, it doesn"t serve gay kids, and (off the record) it"s just a return to the bad old days when unenlightened, sex-hating harpies ran sex education." According to Wetzstein, some proponents of abstinence-only programs believe that another factor -- which is "never mentioned" in the sex education debate -- "is how sexually active youth are part of the market for certain commercial sex- and disease-related products, and abstinent behavior reduces that market share."Wetzstein reports that she recently spoke with Pam Mullarkey, founder of Project SOS, who is "furious" that Presdient Obama"s budget proposal would reduce funding for abstinence-only programs and increase money for teen pregnancy prevention. Mullarkey claims that abstinence-only opponents "have spent so much money trying to destroy abstinence education" because "it directly costs them big bucks" if teens abstain. Wetzstein writes that she has "dim hopes for the survival of abstinence education as we"ve know it," concluding, "But should Congress decide to "follow the money," as Mrs. Mullarkey suggests, who knows what might turn up" (Wetzstein, Washington Times, 5/19).
generic viagra online
US Oncology Research Network Participates In Phase III Follow-up Study To BiPar's Investigational Cancer Drug BSI-201
US Oncology, Inc. today announced that US Oncology Research will participate in the BiPar Sciences" Phase III, Multi-center, Open-Label, Randomized Trial of Gemcitabine/Carboplatin (G/C), with or without BSI-201, in patients with Estrogen Receptor (ER), Progesterone Receptor (PR), and HER2-negative metastatic breast cancer.
News of the day
Insights Into Failed HIV-1 Vaccine Trial: Study
Following the disbandment of the STEP trial to test the efficacy of the Merck HIV-1 vaccine candidate in 2007, the leading explanation for why the vaccine was ineffective - and may have even increased susceptibility to acquiring the virus - centered on the hypothesis that high levels of baseline Ad5-specific neutralizing antibodies may have increased HIV-1 acquisition among the study subjects who received the vaccine by increasing Ad5-specific CD4+ T-cells that were susceptible to HIV-1 infection.
Nutrition

The European Biotech Industry Applauds UK Efforts To Place Industrial Biotech At The Center Of A Low Carbon Economy

EuropaBio, the European biotech industry association applauds the report "IB 2025: Maximising UK Opportunities from Industrial Biotechnology in a Low Carbon Economy" (1) released today by the UK"s Department for Business Enterprise and Regulatory Reform (BERR). The biotech industry welcomes the report which is completely in line with the EU"s Lead Market Initiative for Biobased Products (2). EuropaBio is also pleased to note that the report also embraces EuropaBio"s policy recommendations (3) developed to help the EU realise the vision of a Knowledge-Based Bio-Economy (KBBE). "A competitive European Knowledge-based Bioeconomy can only be realised when the European Union and the member states put a coherent policy framework in place. What has been done in the UK will motivate industry to continue investment in this emerging and innovative industrial sector" said Dirk Carrez, EuropaBio"s Director, Industrial Biotechnology. Over the last two years the biotech industry has supported the European Commission to work out a set of concrete steps to realise the vision of a Knowledge-Based Bio-Economy (KBBE), where biotechnology"s new, clean, energy-efficient processes and innovative biobased products create a sustainable industrial base to ensure Europe"s future prosperity. EuropaBio"s "Industrial Biotechnology Policy Agenda for Europe" (3) produced an outline of policy recommendations to develop a competitive KBBE in Europe, but recognized that in order for these recommendations to be implemented, political support was needed. "EuropaBio is pleased to note the support these recommendations have received from the UK government" said Willy De Greef, EuropaBio"s Secretary General. "Developing an innovation driven economy is at the core of the Lisbon partnership. It is only with support of the member states that the vision to support growth and jobs in Europe by stimulating innovation can be realized." Notes (1) IB 2025: Maximising UK Opportunities from Industrial Biotechnology in a Low Carbon Economy See here. (2) The Commission Website on the Lead Market Initiative (3) Industrial Biotechnology Policy Agenda for Europe EuropaBio


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009